Global Cryopreservation Bags Market Size, Trends & Growth Opportunity By Product Type, By Application, By End User, By Cell Type, By Region and Forecast Till 2030

Report ID : AMR1005968 | Industries : Healthcare | Published On :August 2026 | Page Count : 279

Request Sample
Ask for Customization

Cryopreservation Bags Market Overview & Definition

The global cryopreservation bags market covers cryopreservation bags and related cell and gene therapy manufacturing consumables supplied worldwide.

A cryopreservation bag is a flexible container engineered to hold cells or biological material at ultra-low or cryogenic temperatures, and this report describes the category strictly as a market segment.

It makes no claim about cryogenic performance effectiveness, sterility assurance effectiveness, cell viability outcomes, GMP compliance effectiveness, or any clinical or therapeutic outcome for any product or company described on these pages.

Ten segmentation dimensions appear in this report, and the first two describe the product type supplied and the material it is manufactured from.

Product type spans six categories, from single chamber and dual chamber bags through multi-chamber bags, transfer bags, storage bags and customised cryogenic bags.

Material covers five categories, spanning Ethylene Vinyl Acetate (EVA), Polyolefin, fluoropolymer-based materials, multilayer films and specialty cryogenic polymers.

The most useful commercial observation about this market is that chamber configuration, not product type category alone, is the first specification decision a buyer actually makes.

A process's fill and separation requirements determine which of the six product type categories are even viable before material is considered.

Capacity spans four bands from below 50 mL to above 500 mL, sterility format covers three categories including gamma sterilised, Ethylene Oxide (EO) sterilised and ready-to-use sterile systems, temperature rating spans three categories including -80°C storage, liquid nitrogen vapor phase and liquid nitrogen immersion compatible, and manufacturing standard completes a further dimension across research grade, clinical grade and Good Manufacturing Practice (GMP) grade.

Cell type is the widest dimension in this report at nine categories, spanning stem cells, Chimeric Antigen Receptor T-Cell (CAR-T) cells, Natural Killer (NK) cells, T cells, Peripheral Blood Mononuclear Cells (PBMC), cord blood, bone marrow, Mesenchymal Stem Cells (MSC) and induced Pluripotent Stem Cells (iPSC), and application covers a further nine categories.

End user spans nine categories including cell therapy manufacturers, Contract Development and Manufacturing Organisations (CDMOs) and biopharmaceutical companies, and purchasing model completes the segmentation across five categories including direct procurement, OEM supply, distributor sales, long-term supply agreements and project-based procurement.

This report covers cryopreservation bags and related cell and gene therapy manufacturing consumables supplied across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

It excludes rigid cryovials, cryogenic freezers and storage equipment, and non-cryogenic single-use bioprocessing bags outside this report's cryopreservation bag scope.

Customer intelligence in the full report maps cell therapy developers, gene therapy developers, biopharmaceutical manufacturers, CDMOs and academic research centres across the five regions this report covers.

Competitive benchmarking compares manufacturers across estimated market position, product portfolio, GMP manufacturing, global distribution and ten further metrics without disclosing proprietary competitive positioning data.

Market Size & Growth Forecast (2026 to 2030)

The global cryopreservation bags market is estimated at approximately USD 285 Million in 2025 and is projected to reach approximately USD 520 Million by 2030, expanding at a compound annual growth rate of roughly 12.8 percent.

The estimate covers cryopreservation bags and related cell and gene therapy manufacturing consumables, and excludes rigid cryovials and cryogenic freezers and storage equipment.

Dual chamber and multi-chamber bags together account for the largest product type category by revenue, while customised cryogenic bags form the fastest-growing product type category.

GMP grade bags account for the largest manufacturing standard category by revenue, and clinical grade forms a fast-growing category tied to expanding clinical trial activity.

Stem cells and CAR-T cells together account for the largest cell type category by revenue, while NK cells and iPSC together form a fast-growing cell type category.

Cell therapy manufacturing accounts for the largest application category by revenue, and gene therapy manufacturing forms the fastest-growing application category.

Cell therapy manufacturers and CDMOs together account for the largest end user category, and biopharmaceutical companies form a fast-growing end user category.

Long-term supply agreements and direct procurement together account for the largest purchasing model category, and OEM supply forms a fast-growing purchasing category.

North America accounts for the largest regional concentration in this report, and Asia-Pacific forms a fast-growing region tied to expanding cell therapy manufacturing capacity.

The forecast assumes global cell and gene therapy manufacturing investment continues broadly on recent trends, and a sustained slowdown in clinical and commercial manufacturing capacity investment would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 285 Million
Forecast Size (2030)Approximately USD 520 Million
CAGR (2025-2030)Approximately 12.8%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteCryopreservation bags and related cell and gene therapy manufacturing consumables only; excludes rigid cryovials and cryogenic freezers
Largest Product CategoryDual chamber and multi-chamber bags
Fastest-Growing Product CategoryCustomised cryogenic bags
Largest Application CategoryCell therapy manufacturing
Fastest-Growing ApplicationGene therapy manufacturing
Largest Manufacturing StandardGMP grade
Largest Regional ConcentrationNorth America

Market Drivers

Growth in cell and gene therapy clinical trial activity and commercial manufacturing capacity, both of which specify cryopreservation bags as a core process consumable.

Rising biobanking and cell banking investment among academic, government and commercial research institutions.

Expansion of GMP-grade manufacturing facility construction, driving demand for validated, clinically qualified cryopreservation bag formats.

Growth in regenerative medicine and advanced therapy medicinal product development, broadening cryopreservation bag demand beyond traditional cell therapy manufacturing.

Rising demand for ready-to-use sterile systems, which reduce qualification burden for manufacturers scaling from clinical to commercial supply.

Increasing adoption of dual chamber and multi-chamber bag configurations as cell processing workflows grow more complex.

Growth in blood banking and IVF laboratory demand, broadening the end-user base beyond cell therapy manufacturers and CDMOs alone.

Expansion of dual supplier strategies among large biopharma buyers, increasing the addressable supplier base for qualified manufacturers.

Growth in vaccine development programmes, which increasingly specify cryopreservation bags for intermediate and bulk material storage.

Market Restraints

Dependence on cell and gene therapy manufacturing investment cycles, which govern new demand and are outside any manufacturer's control.

Specialty polymer raw material price volatility, which bears directly on product pricing and margin given the material-intensive nature of cryopreservation bag manufacturing.

Long GMP qualification and vendor validation periods before a cell therapy manufacturer or CDMO approves a new supplier.

Competition between global manufacturers, regional life science specialists, custom OEM manufacturers, premium GMP suppliers and cost-focused suppliers, which fragments technical and commercial preference.

Fragmented demand across smaller emerging cell therapy companies, which raises the cost of serving that segment commercially relative to large global biopharma accounts.

Extensive regulatory documentation requirements across multiple jurisdictions, which can lengthen a manufacturer's time to qualification for a new customer.

Long qualification periods before a biopharmaceutical company approves a new manufacturer for a commercial manufacturing contract.

Skilled quality and regulatory affairs personnel availability constraints, which can affect both new product development and ongoing customer qualification support.

Extended chain-of-custody documentation obligations for clinical-stage material, which add ongoing compliance cost beyond the initial supply relationship.

Market Opportunities

Considerable untapped opportunity identified in the report competitive mapping.

Product innovation gaps and regional supply gaps relative to the concentration of established manufacturing capacity among global manufacturers.

Premium GMP segment and clinical manufacturing segment opportunities identified in the report competitive mapping.

Growth in emerging markets and emerging cell therapy company accounts, where fewer manufacturers have established deep customer relationships.

Underserved demand in gene therapy manufacturing accounts, where fewer manufacturers have established deep application-specific expertise.

Expansion of custom engineering capability, which several manufacturers are using to differentiate their specification and validation support.

Growth in dual supplier programmes among large biopharma buyers, offering a growing alternative demand pool to single-supplier relationships.

Multi-standard manufacturing capability, which reduces the number of separate qualification processes a manufacturer must maintain across varied customer specifications.

Product Types and Materials

Single chamber, dual chamber, multi-chamber, transfer, storage and customised cryogenic bags are manufactured from EVA, Polyolefin, fluoropolymer-based materials, multilayer films and specialty cryogenic polymers. Full detail is covered on the cryopreservation bag product types and materials page.

Capacity, Sterility and Temperature Ratings

Below 50 mL, 50-250 mL, 250-500 mL and above 500 mL capacity bags are supplied in gamma sterilised, EO sterilised and ready-to-use sterile formats, rated for -80°C storage, liquid nitrogen vapor phase and liquid nitrogen immersion compatible conditions, manufactured to research grade, clinical grade and GMP grade standards. Full detail is covered on the cryopreservation bag capacity, sterility and temperature ratings page.

Cell Types and Applications

Stem cells, CAR-T cells, NK cells, T cells, PBMC, cord blood, bone marrow, MSC and iPSC are stored and processed across cell therapy manufacturing, gene therapy manufacturing, cell banking, biobanking, clinical trial storage, regenerative medicine, vaccine development, blood component preservation and cell transportation. Full detail is covered on the cryopreservation bag cell types and applications page.

End Users and Purchasing Models

Cell therapy manufacturers, CDMOs, biopharmaceutical companies, research institutes, academic centres, hospitals, blood banks, biobanks and IVF laboratories purchase through direct procurement, OEM supply, distributor sales, long-term supply agreements and project-based procurement. Full detail is covered on the cryopreservation bag end users and purchasing models page.

Cryopreservation Bags Market, By Region

This report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa, reflecting where global cell and gene therapy manufacturing activity is concentrated.

North America accounts for the largest regional concentration in this report, covered through the United States and Canada, with demand clustered around Boston, the San Francisco Bay Area, San Diego, the Research Triangle and Toronto.

Europe represents a substantial regional concentration, covered through Germany, the United Kingdom, France, Switzerland, Italy and the Netherlands, with demand clustered around Cambridge, Basel, Heidelberg and Leiden.

Asia-Pacific forms a fast-growing region tied to expanding cell therapy manufacturing capacity, covered through China, Japan, South Korea, India, Singapore and Australia, with demand clustered around Singapore, Shanghai, Tokyo and Seoul.

Latin America and the Middle East and Africa together form a smaller but steadily developing regional grouping, covered through Brazil, Mexico, Israel, the United Arab Emirates, Saudi Arabia and South Africa.

Regional sizing, growth rates and country-level breakdowns are reserved for the full report rather than presented on this page.

Leading Companies

CellBios, Sartorius AG, Cytiva, Thermo Fisher Scientific, Fresenius Kabi, OriGen Biomedical, Charter Medical, Saint-Gobain Life Sciences, Entegris, Single Use Support, PBS Biotech, Meissner Corporation, AdvaCare Pharma, RENOLIT Healthcare and Cellon SA are covered in the full report. An introduction to the supplier landscape by company type is available on the leading cryopreservation bag manufacturers page.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how cryopreservation bag supply is actually won.

Customer intelligence maps the buyer ecosystem across cell therapy developers, gene therapy developers, biopharmaceutical manufacturers, CDMOs and academic research centres in full.

Decision-maker mapping covers vendor selection criteria, purchase value bands, budget ownership and the full customer lifecycle from technology evaluation through long-term strategic partnership.

Competitive benchmarking compares manufacturers across product portfolio, GMP manufacturing, global distribution, regulatory documentation and manufacturing capacity.

The market playbook covers manufacturing cost structure, polymer raw material trends, GMP compliance roadmap and cold chain infrastructure.

Pricing and procurement chapters cover regional pricing analysis, material cost structure, gross margin analysis and total cost of ownership analysis.

Go-to-market chapters set out entry strategy by geography, CDMO collaboration strategy, GMP qualification roadmap and major industry conference activity.

Company profiles cover fifteen manufacturers across manufacturing footprint, product portfolio, certifications and R&D pipeline.

Frequently Asked Questions

A flexible container engineered to hold cells or biological material at ultra-low or cryogenic temperatures. This report describes the category strictly as a market segment.

The market is estimated at approximately USD 285 Million in 2025 and is projected to reach approximately USD 520 Million by 2030, expanding at a compound annual growth rate of roughly 12.8 percent.

North America accounts for the largest regional concentration, covered through the United States and Canada, with demand clustered around Boston, the San Francisco Bay Area, San Diego, the Research Triangle and Toronto.

Growth in cell and gene therapy clinical trial activity and commercial manufacturing capacity is the leading driver, both of which specify cryopreservation bags as a core process consumable.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Global Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Growth in Cell and Gene Therapy Clinical Trial Activity and Commercial Manufacturing Capacity, Both of Which Specify Cryopreservation Bags as a Core Process Consumable.

3.3.2. Rising Biobanking and Cell Banking Investment Among Academic, Government and Commercial Research Institutions.

3.3.3. Expansion of GMP-Grade Manufacturing Facility Construction, Driving Demand for Validated, Clinically Qualified Cryopreservation Bag Formats.

3.3.4. Growth in Regenerative Medicine and Advanced Therapy Medicinal Product Development, Broadening Cryopreservation Bag Demand Beyond Traditional Cell Therapy Manufacturing.

3.4. Restraints

3.4.1. Dependence on Cell and Gene Therapy Manufacturing Investment Cycles, Which Govern New Demand and Are Outside Any Manufacturer's Control.

3.4.2. Specialty Polymer Raw Material Price Volatility, Which Bears Directly on Product Pricing and Margin Given the Material-Intensive Nature of Cryopreservation Bag Manufacturing.

3.4.3. Long GMP Qualification and Vendor Validation Periods Before a Cell Therapy Manufacturer or CDMO Approves a New Supplier.

3.4.4. Competition Between Global Manufacturers, Regional Life Science Specialists, Custom OEM Manufacturers, Premium GMP Suppliers and Cost-Focused Suppliers, Which Fragments Technical and Commercial Preference.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity Identified in the Report Competitive Mapping.

3.5.2. Product Innovation Gaps and Regional Supply Gaps Relative to the Concentration of Established Manufacturing Capacity Among Global Manufacturers.

3.5.3. Premium GMP Segment and Clinical Manufacturing Segment Opportunities Identified in the Report Competitive Mapping.

3.5.4. Growth in Emerging Markets and Emerging Cell Therapy Company Accounts, Where Fewer Manufacturers Have Established Deep Customer Relationships.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Product Type

4.1. Single Chamber Cryopreservation Bags

4.2. Dual Chamber Bags

4.3. Multi-Chamber Bags

4.4. Transfer Bags

4.5. Storage Bags

4.6. Customised Cryogenic Bags

5. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Material

5.1. Ethylene Vinyl Acetate (EVA)

5.2. Polyolefin

5.3. Fluoropolymer-Based Materials

5.4. Multilayer Films

5.5. Specialty Cryogenic Polymers

6. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Capacity

6.1. Below 50 mL

6.2. 50-250 mL

6.3. 250-500 mL

6.4. Above 500 mL

7. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Sterility Format

7.1. Gamma Sterilised

7.2. Ethylene Oxide (EO) Sterilised

7.3. Ready-to-Use Sterile Systems

8. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Temperature Rating

8.1. -80°C Storage

8.2. Liquid Nitrogen Vapor Phase

8.3. Liquid Nitrogen Immersion Compatible

9. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Manufacturing Standard

9.1. Research Grade

9.2. Clinical Grade

9.3. Good Manufacturing Practice (GMP) Grade

10. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Cell Type

10.1. Stem Cells

10.2. Chimeric Antigen Receptor T-Cell (CAR-T) Cells

10.3. Natural Killer (NK) Cells

10.4. T Cells

10.5. Peripheral Blood Mononuclear Cells (PBMC)

10.6. Cord Blood

10.7. Bone Marrow

10.8. Mesenchymal Stem Cells (MSC)

10.9. Induced Pluripotent Stem Cells (iPSC)

11. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Application

11.1. Cell Therapy Manufacturing

11.2. Gene Therapy Manufacturing

11.3. Cell Banking

11.4. Biobanking

11.5. Clinical Trial Storage

11.6. Regenerative Medicine

11.7. Vaccine Development

11.8. Blood Component Preservation

11.9. Cell Transportation

12. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, End User

12.1. Cell Therapy Manufacturers

12.2. Contract Development and Manufacturing Organisations (CDMOs)

12.3. Biopharmaceutical Companies

12.4. Research Institutes

12.5. Academic Centres

12.6. Hospitals

12.7. Blood Banks

12.8. Biobanks

12.9. In Vitro Fertilisation (IVF) Laboratories

12.10. Contract Research Organisations

13. Cryopreservation Bags Market - Global View of Cell and Gene Therapy Manufacturing Consumables with Spotlight on Product Types, Materials, Capacities, Sterility Formats, Temperature Ratings, Manufacturing Standards, Cell Types, Applications, End Users, Purchasing Models, Customer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Purchasing Model

13.1. Direct Procurement

13.2. OEM Supply

13.3. Distributor Sales

13.4. Long-Term Supply Agreements

13.5. Project-Based Procurement

14. Customer Intelligence and Demand Landscape

14.1. Customer Segmentation

14.1.1. Cell Therapy Developers

14.1.2. Gene Therapy Developers

14.1.3. Biopharmaceutical Manufacturers

14.1.4. CDMOs

14.1.5. Academic Research Centres

14.1.6. Biobanks

14.1.7. Blood Banks

14.1.8. Government Research Institutes

14.2. Customer Industries

14.2.1. Biopharmaceutical Manufacturing

14.2.2. Advanced Therapy Medicinal Products (ATMP)

14.2.3. Regenerative Medicine

14.2.4. Clinical Research

14.2.5. Life Science Research

14.2.6. Precision Medicine

14.3. Customer Organisation Size

14.3.1. Global Biopharma

14.3.2. Mid-Sized Biotechnology Firms

14.3.3. Emerging Cell Therapy Companies

14.3.4. Academic Institutions

14.3.5. Government Laboratories

14.4. Geographic Demand Clusters

14.4.1. Boston

14.4.2. San Francisco Bay Area

14.4.3. San Diego

14.4.4. Research Triangle

14.4.5. Toronto

14.4.6. Cambridge (UK)

14.4.7. Basel

14.4.8. Heidelberg

14.4.9. Leiden

14.4.10. Singapore

14.4.11. Shanghai

14.4.12. Tokyo

14.4.13. Seoul

14.5. Procurement Behaviour

14.5.1. GMP Qualification Requirements

14.5.2. Vendor Validation

14.5.3. Long-Term Supply Contracts

14.5.4. Dual Supplier Strategy

14.5.5. Quality Audits

14.5.6. Regulatory Documentation Review

14.6. Buying Triggers

14.6.1. New GMP Facilities

14.6.2. Clinical Trial Expansion

14.6.3. Commercial Manufacturing

14.6.4. Capacity Expansion

14.6.5. Technology Transfer

14.7. Decision Makers

14.7.1. VP Manufacturing

14.7.2. Head of Cell Therapy

14.7.3. Procurement Director

14.7.4. Manufacturing Director

14.7.5. Quality Director

14.7.6. Technical Operations

14.7.7. Supply Chain Director

14.8. Budget Ownership

14.8.1. Manufacturing

14.8.2. Process Development

14.8.3. Clinical Operations

14.8.4. Capital Projects

14.8.5. Procurement

14.9. Vendor Selection Criteria

14.9.1. Cryogenic Performance

14.9.2. Film Quality

14.9.3. Sterility Assurance

14.9.4. GMP Documentation

14.9.5. Regulatory Support

14.9.6. Validation Package

14.9.7. Supply Reliability

14.9.8. Global Availability

14.10. Purchase Value Bands

14.10.1. Laboratory Purchases

14.10.2. Clinical Program Procurement

14.10.3. Commercial Manufacturing Contracts

14.10.4. Enterprise Supply Agreements

14.11. Customer Lifecycle

14.11.1. Technology Evaluation

14.11.2. Qualification

14.11.3. Process Validation

14.11.4. Clinical Supply

14.11.5. Commercial Supply

14.11.6. Long-Term Strategic Partnership

15. Global Market Analysis and Forecast (2026–2030)

15.1. Introduction

15.2. Market Share Analysis

15.3. Market Size and Forecast

15.4. Market Size and Forecast, By Geography

15.4.1. North America

15.4.1.1. Market Share Analysis

15.4.1.2. Market Size and Forecast

15.4.1.3. By Product

15.4.1.4. By Technology

15.4.1.5. By Application

15.4.1.6. By Customer

15.4.1.7. United States

15.4.1.7.1. Market Share Analysis

15.4.1.7.2. Market Size and Forecast

15.4.1.7.3. By Product

15.4.1.7.4. By Technology

15.4.1.7.5. By Application

15.4.1.7.6. By Customer

15.4.1.8. Canada

15.4.1.8.1. Market Share Analysis

15.4.1.8.2. Market Size and Forecast

15.4.1.8.3. By Product

15.4.1.8.4. By Technology

15.4.1.8.5. By Application

15.4.1.8.6. By Customer

15.4.2. Europe

15.4.2.1. Market Share Analysis

15.4.2.2. Market Size and Forecast

15.4.2.3. By Product

15.4.2.4. By Technology

15.4.2.5. By Application

15.4.2.6. By Customer

15.4.2.7. Germany

15.4.2.7.1. Market Share Analysis

15.4.2.7.2. Market Size and Forecast

15.4.2.7.3. By Product

15.4.2.7.4. By Technology

15.4.2.7.5. By Application

15.4.2.7.6. By Customer

15.4.2.8. United Kingdom

15.4.2.8.1. Market Share Analysis

15.4.2.8.2. Market Size and Forecast

15.4.2.8.3. By Product

15.4.2.8.4. By Technology

15.4.2.8.5. By Application

15.4.2.8.6. By Customer

15.4.2.9. France

15.4.2.9.1. Market Share Analysis

15.4.2.9.2. Market Size and Forecast

15.4.2.9.3. By Product

15.4.2.9.4. By Technology

15.4.2.9.5. By Application

15.4.2.9.6. By Customer

15.4.2.10. Switzerland

15.4.2.10.1. Market Share Analysis

15.4.2.10.2. Market Size and Forecast

15.4.2.10.3. By Product

15.4.2.10.4. By Technology

15.4.2.10.5. By Application

15.4.2.10.6. By Customer

15.4.2.11. Italy

15.4.2.11.1. Market Share Analysis

15.4.2.11.2. Market Size and Forecast

15.4.2.11.3. By Product

15.4.2.11.4. By Technology

15.4.2.11.5. By Application

15.4.2.11.6. By Customer

15.4.2.12. Netherlands

15.4.2.12.1. Market Share Analysis

15.4.2.12.2. Market Size and Forecast

15.4.2.12.3. By Product

15.4.2.12.4. By Technology

15.4.2.12.5. By Application

15.4.2.12.6. By Customer

15.4.3. Asia-Pacific

15.4.3.1. Market Share Analysis

15.4.3.2. Market Size and Forecast

15.4.3.3. By Product

15.4.3.4. By Technology

15.4.3.5. By Application

15.4.3.6. By Customer

15.4.3.7. China

15.4.3.7.1. Market Share Analysis

15.4.3.7.2. Market Size and Forecast

15.4.3.7.3. By Product

15.4.3.7.4. By Technology

15.4.3.7.5. By Application

15.4.3.7.6. By Customer

15.4.3.8. Japan

15.4.3.8.1. Market Share Analysis

15.4.3.8.2. Market Size and Forecast

15.4.3.8.3. By Product

15.4.3.8.4. By Technology

15.4.3.8.5. By Application

15.4.3.8.6. By Customer

15.4.3.9. South Korea

15.4.3.9.1. Market Share Analysis

15.4.3.9.2. Market Size and Forecast

15.4.3.9.3. By Product

15.4.3.9.4. By Technology

15.4.3.9.5. By Application

15.4.3.9.6. By Customer

15.4.3.10. India

15.4.3.10.1. Market Share Analysis

15.4.3.10.2. Market Size and Forecast

15.4.3.10.3. By Product

15.4.3.10.4. By Technology

15.4.3.10.5. By Application

15.4.3.10.6. By Customer

15.4.3.11. Singapore

15.4.3.11.1. Market Share Analysis

15.4.3.11.2. Market Size and Forecast

15.4.3.11.3. By Product

15.4.3.11.4. By Technology

15.4.3.11.5. By Application

15.4.3.11.6. By Customer

15.4.3.12. Australia

15.4.3.12.1. Market Share Analysis

15.4.3.12.2. Market Size and Forecast

15.4.3.12.3. By Product

15.4.3.12.4. By Technology

15.4.3.12.5. By Application

15.4.3.12.6. By Customer

15.4.4. Latin America

15.4.4.1. Market Share Analysis

15.4.4.2. Market Size and Forecast

15.4.4.3. By Product

15.4.4.4. By Technology

15.4.4.5. By Application

15.4.4.6. By Customer

15.4.4.7. Brazil

15.4.4.7.1. Market Share Analysis

15.4.4.7.2. Market Size and Forecast

15.4.4.7.3. By Product

15.4.4.7.4. By Technology

15.4.4.7.5. By Application

15.4.4.7.6. By Customer

15.4.4.8. Mexico

15.4.4.8.1. Market Share Analysis

15.4.4.8.2. Market Size and Forecast

15.4.4.8.3. By Product

15.4.4.8.4. By Technology

15.4.4.8.5. By Application

15.4.4.8.6. By Customer

15.4.5. Middle East and Africa

15.4.5.1. Market Share Analysis

15.4.5.2. Market Size and Forecast

15.4.5.3. By Product

15.4.5.4. By Technology

15.4.5.5. By Application

15.4.5.6. By Customer

15.4.5.7. Israel

15.4.5.7.1. Market Share Analysis

15.4.5.7.2. Market Size and Forecast

15.4.5.7.3. By Product

15.4.5.7.4. By Technology

15.4.5.7.5. By Application

15.4.5.7.6. By Customer

15.4.5.8. United Arab Emirates

15.4.5.8.1. Market Share Analysis

15.4.5.8.2. Market Size and Forecast

15.4.5.8.3. By Product

15.4.5.8.4. By Technology

15.4.5.8.5. By Application

15.4.5.8.6. By Customer

15.4.5.9. Saudi Arabia

15.4.5.9.1. Market Share Analysis

15.4.5.9.2. Market Size and Forecast

15.4.5.9.3. By Product

15.4.5.9.4. By Technology

15.4.5.9.5. By Application

15.4.5.9.6. By Customer

15.4.5.10. South Africa

15.4.5.10.1. Market Share Analysis

15.4.5.10.2. Market Size and Forecast

15.4.5.10.3. By Product

15.4.5.10.4. By Technology

15.4.5.10.5. By Application

15.4.5.10.6. By Customer

16. Competition Analysis

16.1. Market Positioning Overview

16.1.1. Label

16.1.2. Items

16.2. Competitive Benchmarking Metrics

16.2.1. Label

16.2.2. Items

16.3. Strategic Moves

16.3.1. Label

16.3.2. Items

16.4. Competitive Mapping & Gaps

16.4.1. Label

16.4.2. Items

17. Company Profiles

17.1. CellBios

17.1.1. Company Overview

17.1.2. Headquarters

17.1.3. Ownership Structure

17.1.4. Year Founded

17.1.5. Workforce Estimate

17.1.6. Geographic Presence

17.1.7. Cryopreservation Product Portfolio

17.1.8. Target Customer Segments

17.1.9. Distribution and Go-to-Market Strategy

17.1.10. Financial Highlights

17.1.11. GMP and Quality Certifications

17.1.12. Strategic Partnerships

17.1.13. Research and Development (R&D) Pipeline

17.1.14. Recent Developments

17.1.15. SWOT Analysis

17.2. Sartorius AG

17.2.1. Company Overview

17.2.2. Headquarters

17.2.3. Ownership Structure

17.2.4. Year Founded

17.2.5. Workforce Estimate

17.2.6. Geographic Presence

17.2.7. Cryopreservation Product Portfolio

17.2.8. Target Customer Segments

17.2.9. Distribution and Go-to-Market Strategy

17.2.10. Financial Highlights

17.2.11. GMP and Quality Certifications

17.2.12. Strategic Partnerships

17.2.13. Research and Development (R&D) Pipeline

17.2.14. Recent Developments

17.2.15. SWOT Analysis

17.3. Cytiva

17.3.1. Company Overview

17.3.2. Headquarters

17.3.3. Ownership Structure

17.3.4. Year Founded

17.3.5. Workforce Estimate

17.3.6. Geographic Presence

17.3.7. Cryopreservation Product Portfolio

17.3.8. Target Customer Segments

17.3.9. Distribution and Go-to-Market Strategy

17.3.10. Financial Highlights

17.3.11. GMP and Quality Certifications

17.3.12. Strategic Partnerships

17.3.13. Research and Development (R&D) Pipeline

17.3.14. Recent Developments

17.3.15. SWOT Analysis

17.4. Thermo Fisher Scientific

17.4.1. Company Overview

17.4.2. Headquarters

17.4.3. Ownership Structure

17.4.4. Year Founded

17.4.5. Workforce Estimate

17.4.6. Geographic Presence

17.4.7. Cryopreservation Product Portfolio

17.4.8. Target Customer Segments

17.4.9. Distribution and Go-to-Market Strategy

17.4.10. Financial Highlights

17.4.11. GMP and Quality Certifications

17.4.12. Strategic Partnerships

17.4.13. Research and Development (R&D) Pipeline

17.4.14. Recent Developments

17.4.15. SWOT Analysis

17.5. Fresenius Kabi

17.5.1. Company Overview

17.5.2. Headquarters

17.5.3. Ownership Structure

17.5.4. Year Founded

17.5.5. Workforce Estimate

17.5.6. Geographic Presence

17.5.7. Cryopreservation Product Portfolio

17.5.8. Target Customer Segments

17.5.9. Distribution and Go-to-Market Strategy

17.5.10. Financial Highlights

17.5.11. GMP and Quality Certifications

17.5.12. Strategic Partnerships

17.5.13. Research and Development (R&D) Pipeline

17.5.14. Recent Developments

17.5.15. SWOT Analysis

17.6. OriGen Biomedical

17.6.1. Company Overview

17.6.2. Headquarters

17.6.3. Ownership Structure

17.6.4. Year Founded

17.6.5. Workforce Estimate

17.6.6. Geographic Presence

17.6.7. Cryopreservation Product Portfolio

17.6.8. Target Customer Segments

17.6.9. Distribution and Go-to-Market Strategy

17.6.10. Financial Highlights

17.6.11. GMP and Quality Certifications

17.6.12. Strategic Partnerships

17.6.13. Research and Development (R&D) Pipeline

17.6.14. Recent Developments

17.6.15. SWOT Analysis

17.7. Charter Medical

17.7.1. Company Overview

17.7.2. Headquarters

17.7.3. Ownership Structure

17.7.4. Year Founded

17.7.5. Workforce Estimate

17.7.6. Geographic Presence

17.7.7. Cryopreservation Product Portfolio

17.7.8. Target Customer Segments

17.7.9. Distribution and Go-to-Market Strategy

17.7.10. Financial Highlights

17.7.11. GMP and Quality Certifications

17.7.12. Strategic Partnerships

17.7.13. Research and Development (R&D) Pipeline

17.7.14. Recent Developments

17.7.15. SWOT Analysis

17.8. Saint-Gobain Life Sciences

17.8.1. Company Overview

17.8.2. Headquarters

17.8.3. Ownership Structure

17.8.4. Year Founded

17.8.5. Workforce Estimate

17.8.6. Geographic Presence

17.8.7. Cryopreservation Product Portfolio

17.8.8. Target Customer Segments

17.8.9. Distribution and Go-to-Market Strategy

17.8.10. Financial Highlights

17.8.11. GMP and Quality Certifications

17.8.12. Strategic Partnerships

17.8.13. Research and Development (R&D) Pipeline

17.8.14. Recent Developments

17.8.15. SWOT Analysis

17.9. Entegris

17.9.1. Company Overview

17.9.2. Headquarters

17.9.3. Ownership Structure

17.9.4. Year Founded

17.9.5. Workforce Estimate

17.9.6. Geographic Presence

17.9.7. Cryopreservation Product Portfolio

17.9.8. Target Customer Segments

17.9.9. Distribution and Go-to-Market Strategy

17.9.10. Financial Highlights

17.9.11. GMP and Quality Certifications

17.9.12. Strategic Partnerships

17.9.13. Research and Development (R&D) Pipeline

17.9.14. Recent Developments

17.9.15. SWOT Analysis

17.10. Single Use Support

17.10.1. Company Overview

17.10.2. Headquarters

17.10.3. Ownership Structure

17.10.4. Year Founded

17.10.5. Workforce Estimate

17.10.6. Geographic Presence

17.10.7. Cryopreservation Product Portfolio

17.10.8. Target Customer Segments

17.10.9. Distribution and Go-to-Market Strategy

17.10.10. Financial Highlights

17.10.11. GMP and Quality Certifications

17.10.12. Strategic Partnerships

17.10.13. Research and Development (R&D) Pipeline

17.10.14. Recent Developments

17.10.15. SWOT Analysis

17.11. PBS Biotech

17.11.1. Company Overview

17.11.2. Headquarters

17.11.3. Ownership Structure

17.11.4. Year Founded

17.11.5. Workforce Estimate

17.11.6. Geographic Presence

17.11.7. Cryopreservation Product Portfolio

17.11.8. Target Customer Segments

17.11.9. Distribution and Go-to-Market Strategy

17.11.10. Financial Highlights

17.11.11. GMP and Quality Certifications

17.11.12. Strategic Partnerships

17.11.13. Research and Development (R&D) Pipeline

17.11.14. Recent Developments

17.11.15. SWOT Analysis

17.12. Meissner Corporation

17.12.1. Company Overview

17.12.2. Headquarters

17.12.3. Ownership Structure

17.12.4. Year Founded

17.12.5. Workforce Estimate

17.12.6. Geographic Presence

17.12.7. Cryopreservation Product Portfolio

17.12.8. Target Customer Segments

17.12.9. Distribution and Go-to-Market Strategy

17.12.10. Financial Highlights

17.12.11. GMP and Quality Certifications

17.12.12. Strategic Partnerships

17.12.13. Research and Development (R&D) Pipeline

17.12.14. Recent Developments

17.12.15. SWOT Analysis

17.13. AdvaCare Pharma

17.13.1. Company Overview

17.13.2. Headquarters

17.13.3. Ownership Structure

17.13.4. Year Founded

17.13.5. Workforce Estimate

17.13.6. Geographic Presence

17.13.7. Cryopreservation Product Portfolio

17.13.8. Target Customer Segments

17.13.9. Distribution and Go-to-Market Strategy

17.13.10. Financial Highlights

17.13.11. GMP and Quality Certifications

17.13.12. Strategic Partnerships

17.13.13. Research and Development (R&D) Pipeline

17.13.14. Recent Developments

17.13.15. SWOT Analysis

17.14. RENOLIT Healthcare

17.14.1. Company Overview

17.14.2. Headquarters

17.14.3. Ownership Structure

17.14.4. Year Founded

17.14.5. Workforce Estimate

17.14.6. Geographic Presence

17.14.7. Cryopreservation Product Portfolio

17.14.8. Target Customer Segments

17.14.9. Distribution and Go-to-Market Strategy

17.14.10. Financial Highlights

17.14.11. GMP and Quality Certifications

17.14.12. Strategic Partnerships

17.14.13. Research and Development (R&D) Pipeline

17.14.14. Recent Developments

17.14.15. SWOT Analysis

17.15. Cellon SA

17.15.1. Company Overview

17.15.2. Headquarters

17.15.3. Ownership Structure

17.15.4. Year Founded

17.15.5. Workforce Estimate

17.15.6. Geographic Presence

17.15.7. Cryopreservation Product Portfolio

17.15.8. Target Customer Segments

17.15.9. Distribution and Go-to-Market Strategy

17.15.10. Financial Highlights

17.15.11. GMP and Quality Certifications

17.15.12. Strategic Partnerships

17.15.13. Research and Development (R&D) Pipeline

17.15.14. Recent Developments

17.15.15. SWOT Analysis

Frequently Asked Questions

A flexible container engineered to hold cells or biological material at ultra-low or cryogenic temperatures. This report describes the category strictly as a market segment.

The market is estimated at approximately USD 285 Million in 2025 and is projected to reach approximately USD 520 Million by 2030, expanding at a compound annual growth rate of roughly 12.8 percent.

North America accounts for the largest regional concentration, covered through the United States and Canada, with demand clustered around Boston, the San Francisco Bay Area, San Diego, the Research Triangle and Toronto.

Growth in cell and gene therapy clinical trial activity and commercial manufacturing capacity is the leading driver, both of which specify cryopreservation bags as a core process consumable.

Inquire Before Buying Request Free Sample Ask For Discount

Research Methodology

Cryopreservation bags separated from general single-use bioprocessing bag markets

Cryopreservation bags are frequently reported inside the much larger single-use bioprocessing bag or cell processing consumables markets, which span non-cryogenic bag categories not comparable with the activity described here. This estimate covers cryopreservation bags and related cell and gene therapy manufacturing consumables only. The snapshot table states that boundary so the figure is not mistaken for anything larger.

Derivation from cell and gene therapy manufacturing programme volume

Applying observed cryopreservation bag attachment rates per cell type and application, weighted by manufacturing standard and end user, to the estimated population of qualifying cell therapy, gene therapy and biobanking programmes across the five regions this report covers produces an annual range of approximately USD 278 to 292 million for cryopreservation bag supply itself.

GMP grade and commercial-scale categories weighted separately

GMP grade bags used in commercial and late-stage clinical manufacturing carry a materially higher value per unit than research grade categories, and weighting the product mix by observed category share rather than by unit volume alone produces a total range of approximately USD 281 to 289 million, and USD 285 million was adopted near the midpoint.

Forecast basis and its principal sensitivity

The forecast to 2030 assumes global cell and gene therapy manufacturing investment continues broadly on recent trends. Clinical trial and commercial manufacturing capacity expansion pace is the material sensitivity, since cryopreservation bag demand tracks this activity more closely than any product-level trend.

Frequently Asked Questions

A flexible container engineered to hold cells or biological material at ultra-low or cryogenic temperatures. This report describes the category strictly as a market segment.

The market is estimated at approximately USD 285 Million in 2025 and is projected to reach approximately USD 520 Million by 2030, expanding at a compound annual growth rate of roughly 12.8 percent.

North America accounts for the largest regional concentration, covered through the United States and Canada, with demand clustered around Boston, the San Francisco Bay Area, San Diego, the Research Triangle and Toronto.

Growth in cell and gene therapy clinical trial activity and commercial manufacturing capacity is the leading driver, both of which specify cryopreservation bags as a core process consumable.

Inquire Before Buying Request Free Sample Ask For Discount